{"groups":[{"description":"Brentuximab vedotin 1.8 mg/kg every 3 weeks by intravenous (IV) infusion","id":"FG000","title":"Brentuximab Vedotin"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"45"}],"type":"Progressive disease"},{"reasons":[{"groupId":"FG000","numSubjects":"20"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"12"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"7"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"102"}],"type":"STARTED"},{"achievements":[{"comment":"Number who completed 16 cycles of treatment","groupId":"FG000","numSubjects":"18"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"84"}],"type":"NOT COMPLETED"}],"title":"Treatment Period"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"7"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Other"}],"milestones":[{"achievements":[{"comment":"All participants were to be followed after treatment","groupId":"FG000","numSubjects":"102"}],"type":"STARTED"},{"achievements":[{"comment":"Completed survival follow-up due to death \\[57\\] or study termination by sponsor \\[33\\]","groupId":"FG000","numSubjects":"90"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"12"}],"type":"NOT COMPLETED"}],"title":"Follow-up Period"}],"recruitmentDetails":"Enrollment period: Feb 2009 - Aug 2009"}